行情

CALA

CALA

Calithera
NASDAQ

实时行情|Nasdaq Last Sale

7.41
+0.50
+7.24%
盘后: 7.41 0 0.00% 16:00 01/17 EST
开盘
6.97
昨收
6.91
最高
7.64
最低
6.92
成交量
69.28万
成交额
--
52周最高
7.64
52周最低
2.450
市值
3.98亿
市盈率(TTM)
-3.5625
分时
5日
1月
3月
1年
5年

分析师评级

5位分析师的综合评级

强力推荐

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

EPS

CALA 新闻

  • The Daily Biotech Pulse: Nektar Withdraws Opioid Pain Drug NDA, Galapagos Takes Stake In Fibrocor, Integra Lifesciences Lowers Q4 Guidance
  • Benzinga.2天前
  • Calithera Biosciences Expects to Use $75M to $85M of Cash in 2020
  • Benzinga.4天前
  • Calithera Biosciences Provides Overview of 2020 Corporate Milestones and Financial Guidance
  • GlobeNewswire.4天前
  • Week 3 MDA Breakout Forecast: Short-Term Picks To Give You An Edge
  • Seeking Alpha - Article.6天前

更多

所属板块

生物技术和医学研究
-0.16%
制药与医学研究
+0.06%

热门股票

名称
价格
涨跌幅

CALA 简况

Calithera Biosciences, Inc. is a clinical-stage pharmaceutical company. The Company focuses on discovering and developing small molecule drugs directed against tumor and immune cell targets that control key metabolic pathways in the tumor microenvironment. It is engaged in developing agents that take advantage of the metabolic requirements of tumor cells and cancer-fighting immune cells, such as cytotoxic T-cells. The Company's lead product candidate, CB-839, is a critical enzyme in tumor cells. Its other product candidate, CB-1158, is being developed for hematology and oncology indications. CB-1158 is a potent and selective orally bioavailable inhibitor of the enzyme arginase. CB-839 is a selective, reversible and orally bioavailable inhibitor of human glutaminase. CB-1158 has single agent anti-tumor activity in syngeneic mouse tumor models that has been demonstrated to act through an immune mechanism. CB-1158 is being tested in a Phase I clinical trial in patients with solid tumors.
展开

Webull提供Calithera Biosciences Inc的股票价格,实时市场报价,专业分析师评级,深度图表和免费的股票新闻,以帮助您做出投资决策。